Adeno-associated viruses (AAVs) are a promising system for therapeutic gene delivery to neurons in a number of neurodegenerative conditions including spinal cord injuries (SCIs). Considering the role of macrophages and glia in the progression of 'secondary damage', we searched for the optimal vectors for gene transfer to both neurons and glia following contusion SCI in adult rats. Contusion models share many similarities to most human spinal cord traumas. Several AAV serotypes known for their neuronal tropism expressing enhanced green-fluorescent protein (GFP) were injected intraspinally following thoracic T10 contusion. We systematically compared the transduction efficacy and cellular tropism of these vectors for neurons, macrophages/ microglia, oligodendrocytes, astrocytes and NG2-positive glial cells following contusion SCI. No additional changes in inflammatory responses or behavioral performance were observed for any of the vectors. We identified that AAV-rh10 induced robust transduction of both neuronal and glial cells. Even though efficacy to transduce neurons was comparable to already established AAV-1, AAV-5 and AAV-9, AAV-rh10 transduced significantly higher number of macrophages/microglia and oligodendrocytes in damaged spinal cord compared with other serotypes tested. Thus, AAV-rh10 carries promising potential as a gene therapy vector, particularly if both the neuronal and glial cell populations in damaged spinal cord are targeted.
INTRODUCTION
The delivery of therapeutic genes is a developing approach for the treatment of a number of currently incurable medical conditions including spinal cord injuries (SCIs). In the last two decades, recombinant adeno-associated virus (AAV) vectors have emerged as an appropriate delivery vector for gene therapy. Owing to highly favorable characteristics including nonpathogenicity, low immunogenicity, long-lasting gene expression and the ability to transduce dividing and non-dividing cells, [1] [2] [3] AAV has recently been proven to be the safest and most clinically relevant system for delivery of transgenes in mammalian central nervous system (CNS). [4] [5] [6] [7] Many AAV serotypes have been created by cross-packaging of the AAV2 genome with different capsid proteins. 8 The most commonly used and investigated serotypes are AAV-1, -2, -5, -8 and -9. Although different AAV serotypes exhibit different transduction efficacy within the CNS, the majority of examined AAV vectors were found to transduce specifically neurons with low or no efficiency to transduce glial cells, including astrocytes and oligodendrocytes. [9] [10] [11] Specific glial cells could be targeted by using specific glial cell promoters, although with limited neuronal transduction. 12, 13 Vectors with high tropism for both neurons and glial cells are yet to be identified.
Recently, several new serotypes have become available and have been examined for gene transfer in rodent brain. 11, 14 Among these new vectors, AAV-rh10 showed high efficacy to transduce neurons in adult and neonatal rodent brain. 11, [15] [16] [17] [18] AAV-rh10-mediated transduction of other cell types has not been thoroughly examined.
Vast majority of studies comparing transduction efficacy of different viral vectors have been conducted in non-injured CNS. As of anticipated biochemical and cellular changes post injury, the injured spinal cord may not transduce the same as the non-injured one. Within the CNS, many pathological neurological conditions, including SCI, involve altered function of not only neurons but also macrophages and glial cells, including oligodendrocytes and astrocytes. [19] [20] [21] Recent studies suggest that glial response to the injury participates in formation of the astroglial scar and development of the 'hostile' environment at the injury epicenter. Increased levels of inhibitory factors in and around the glial scar in the damaged spinal cord are known to contribute to (i) neuronal death that progresses during the course of secondary injury, 22, 23 (ii) restricted regeneration of damaged axons, 24, 25 (iii) disrupted myelination of lesioned and survived axons 26, 27 and (iv) limited transmission through the surviving axons. 28, 29 These deficits are major burdens that restrict recovery of function following SCI. Thus, identifying viral vectors targeting transfection of glial cells and macrophages/microglia, in addition to neurons, is an important task for determining appropriate vectors for gene delivery into the damaged spinal cord following SCI.
AAV vectors have been used for therapeutic gene delivery to rat brain and spinal cord in different SCI models. [30] [31] [32] [33] [34] [35] [36] Among several animal models of SCI, adult rat contusion models have been established as exhibiting a striking similarity to most human spinal trauma. 37 However, transduction efficacy and cellular tropism of different AAV vectors in the damaged spinal cord have not been systematically examined following contusion SCI. The necessity for therapeutic gene delivery to the lesion cavity prompted us to study AAV-mediated gene delivery to the injury epicenter following contusion SCI. In the current study, we have examined and compared the efficacy of already established AAV serotypes (AAV-1, AAV-5 and AAV-9) and recently developed AAV-rh10 and AAV-hu11 to transduce macrophages/microglia and glial cells in addition to neurons in the damaged spinal cord. In addition, we have examined effects of intraspinal injection of these five AAV vectors on behavioral performance and inflammatory cell response following contusion SCI.
RESULTS
Five AAV (1, 5, 9, rh10 and hu11) serotypes encoding enhanced green-fluorescent protein (GFP) transgene under control of the cytomegalovirus (CMV) promoter were injected intraspinally immediately after contusion SCI (150 kdyn force of IH Impactor) at T10 spinal level. Each vector was injected bilaterally, 1.2 mm rostral and 1.2 mm caudal, 1 mm lateral to midline at 1.5 mm depth, that is, four intraspinal injections, 0.5 μl each (n = 3-5 rats per serotype). Control group received same SCI and no injections. Animals were kept for 10 weeks; body weight and open-field performance using Basso-Beattie-Breshnahan (BBB) scores were evaluated weekly. At 10 weeks post injury and AAV vector administration, spinal cord tissue was collected and GFP signal was used to determine transduction efficacy throughout the spinal cord. Cell-specific markers were used to analyze the transduction efficacy for different cell types. Qualitative evaluation of transduction at the vicinity of injury/injections was performed using the scoring system of Cearley et al.
14 to provide comparisons with studies examining different AAV serotypes in non-injured CNS. Quantitative analyses were performed to determine transduction efficiencies of neuronal and Figure 1 . Transduction efficiency of AAV-1, 5, 9, rh10, hu11 serotypes at different spinal levels following intraspinal injections of these vectors after T10 contusion SCI. Representative fluorescent images of transverse cervical C1 and lumbar L2, and horizontal thoracic T9-T11 sections prepared 10 weeks following SCI and AAVs administration. Note that horizontal T9-T11 images consist of two contiguous images from same section. Arrows point at the GFP+ fibers in lateral white matter. Scale bar is 100 μm.
non-neuronal cells by counting number of cells, calculating transduction area of sections and measuring the GFP intensity of neurons for each viral vector.
Transduction of the spinal cord at the site of injury/vector administration We initially evaluated GFP signal using horizontal sections of T9-T11 spinal segments, that is, close to contusion epicenter (injury at T10). We found that all vectors examined were effective in transduction of spinal cord tissue at the vicinity of SCI (Figure 1 ). Transduction efficiency in neurons, processes and glial cells, however, varied depending on the serotype used. GFP signal and cell morphology/location were used for qualitative analyses of transduction efficiency in the vicinity of injury/vector injections based on the modified scoring system of Cearly et al.
14 ( Table 1) . AAV serotypes 5, 9 and rh10 were the best performers with high GFP expression in cells and processes (Table 1 ). Serotypes 5, 9 and rh10 showed the highest degree of transduced neurons (Table 1) . AAV-1, -5, -9 and -rh10 serotypes showed robust transduction of processes, whereas AAV-hu11 serotype exhibited a lesser degree of GFP-positive processes (Table 1) . AAV-rh10 showed the highest number of GFP-positive glial cells in white and gray matter as well as at the injury epicenter (Table 1) .
Qualitative analyses of GFP expression throughout the spinal cord Neurons. The majority of transduced cells with neuronal morphology in the gray matter were located at the intermediate levels and in the ventral horn ( Figure 3 ). Few GFP-positive cells were observed in the dorsal horn of gray matter. In general, gene expression was localized mostly close to the injection site and declined in distant parts of the cord. AAV-9 and AAV-rh10, however, exhibited better expression in distant lumbar and cervical spinal levels (Figure 1 ). Lumbar and thoracic spinal levels possessed higher number of transduced neurons compared with cervical levels, apparently because of their proximity to the injection site.
Processes. In thoracic and lumbar spinal levels many GFP-positive processes were observed in lateral and ventral funiculi of white matter, with fewer GFP fibers at the dorsal funiculus (Figure 1 ). In the cervical spinal cord, GFP-positive processes were located mostly along the perimeter of white matter ( Figure 1 , at arrows).
Glial cells. Most transduced glial cells (determined by location, size and morphology) were observed close to the injury epicenter, in segments T9-T11, in both white matter and gray matter, as well as at the injury penumbra ( Table 1) .
Quantification of number of transduced neurons
To determine the number of transduced neurons, spinal cord sections (40-μm thick) were immunostained with neuronal marker NeuN (example of horizontal section in Figure 2a) . Results are presented in a graph form in Figure 2b and represent the mean number of transduced neurons per section calculated from five cross-sections separated by 80 μm for each serotype at different spinal levels.
We found that the majority of transduced neurons were located approximately within five segments rostral and caudal (~3 mm) to injection sites. AAV-rh10, AAV-9 and AAV-5 demonstrated the highest overall number of transduced neurons throughout the spinal cord.
In thoracic levels, the number of transduced neurons at T8 and T12 levels for AAV-5 (T8: 65.2 ± 9.6; T12: 73.3 ± 8.4; n = 5 rats), AAV-9 (T8: 69.0 ± 9.4; T12: 80.7 ± 9.5; n = 5 rats) and AAV-rh10 Table 1 . Transduction characteristics of AAV serotypes at T9-T11 segments following contusion SCI at the T10 level and intraspinal injections of vectors close to injury epicenter Scores for AAV-mediated transduction of neurons, processes and glial cells (modified from Cearley et al.
)
Serotypes Neurons Processes Glial cells (n = 5 for AAV-5, AAV-9 and AAV-rh10; n = 4 for AAV-1; n = 3 for AAVhu11). Scale bar is 100 μm.
(T8: 73.1 ± 7.5; T12: 76.1 ± 8.7; n = 5 rats) were significantly higher compared with AAV-1 (T8: 47.0 ± 9.6; T12: 46.2 ± 8.6; n = 4 rats) and AAV-hu11(T8: 34.3 ± 6.2; T12: 31.5 ± 8.6; n = 3 rats; one-way analysis of variance (ANOVA), P o0.05). No significant difference was found between AAV-5, -9 and -rh10 at these levels. Despite some variations in the number of transduced cells, no significant difference was found in other thoracic levels between the serotypes ( Figure 2b ). In lumbar levels, AAV-9 and AAV-rh10 demonstrated the highest number of transduced neurons versus AAV-1, -5 and -hu11. However, no significant difference in number of transduced neurons was found between AAV-5, 9 and AAV-rh10 (Figure 2b) .
In cervical levels, all serotypes showed overall significantly lower numbers of transduced neurons compared with thoracic and lumbar segments (Figure 2b ). Although there was a tendency of higher numbers of transduced neurons in AAV-rh10-and AAV-9-injected animals (Figure 2b ), there was no significant difference observed between serotypes in cervical levels.
GFP intensity of transduced neurons
In order to examine GFP intensity in transduced neurons, we have measured the mean GFP intensity per transduced neuron for each viral vector at different spinal levels. Somas of transduced cells with neuronal morphology were manually outlined and GFP intensity was measured and compared between viral vectors as described in Hutson et al. 38 Note that the GFP signal was native and not amplified by immunostaining.
In T9-T11 levels, AAV-1, AAV-9 and AAV-rh10 showed comparable transduction characteristics; however, AV-5 and AAV-hu11 serotypes demonstrated lower intensity of GFP signal per neuron compared with other serotypes (Figure 3c ). Quantification revealed a statistically significant difference in the GFP intensity per neuron between AAV-5 and -hu11 serotypes compared with other serotypes (one-way ANOVA, P o 0.05; Figure 3c ).
In lumbar segments quantification of GFP intensity showed a pattern similar to thoracic T9-T11 for all serotypes, with AAV-5 and AAV-hu11 demonstrating significantly lower GFP intensity per transduced neuron (Figure 3c , one-way ANOVA, P o0.05).
In the cervical cord, all serotypes exhibited markedly lower intensity per transduced neuron compared with thoracic and lumbar cords. Compared with other serotypes, AAV-rh10 and AAV-9 showed significantly higher intensity per neuron (Figure 3c ).
Transduction area
We also measured the transduction area per section at different spinal levels for each viral vector. Percentage of GFP-positive area versus total area per section was calculated and compared between viral vectors (see Materials and methods). Transduction area represents total transduction efficacy and, therefore, includes transduction of not only neurons but processes and glial cells as well. The mean transduction area per section varied depending on viral vectors and spinal levels examined. In thoracic and lumbar segments, AAV-rh10 and AAV-9 transduced the largest areas, although with no significant difference compared with AAV-1 and AAV-5; AAV-hu11 showed significantly smaller transduced area compared with other vectors (one-way ANOVA, P o0.05; Figure 3d ). In the cervical spinal cord all vectors transduced markedly smaller areas compared with thoracic and lumbar levels. AAV-rh10 and AAV-9 still transduced significantly larger areas compared with all other serotypes in cervical levels (one-way ANOVA, P o 0.05; Figure 3d ).
Cell type specificity in the damaged spinal cord Qualitative analysis suggests that the examined vectors may transduce not only neurons but glial cells as well, with AAV-rh10 showing the best results for glial cell transduction (Table 1) . To determine which cell types could be transduced by AAV vectors, we performed immunostaining with different cell-specific antibodies. We detected the transduction of different types of cells, including neurons in gray matter caudal/rostral to contusion (Figure 4a ), macrophages/microglia at the injury epicenter (Figure 4b ), oligodendrocytes in lateral and ventrolateral white matter caudal/rostral to injury (Figure 4c ), NG2-positive cells in lateral white matter caudal/rostral to injury (Figure 4d ) and astrocytes in dorsal funiculus caudal/rostral to injury (Figure 4e ).
For quantitative analyses among AAV serotypes, we used ED1 (to detect macrophages/microglia) and CC1 (to detect oligodendrocytes) immunostaining. The area of ED1-positive immunoreactivity that was also positive for GFP and the percentage of GFPpositive cells that were also immunolabeled with CC1 were measured (see Materials and methods) and compared between all viral vectors (Figures 5b and c) . We found that AAV-rh10 was the most efficient serotype, transducing ED1-positive macrophages/ microglia (Figures 5a and b) and CC1-positive oligodendrocytes ( Figure 5c ) compared with other serotypes.
Inflammatory response and behavioral performance following AAV administration In this study we examined whether any of the viral vectors tested could potentially induce adverse effects upon behavioral performance and body weight, or induce additional inflammatory response following intraspinal injections of vectors after T10 contusion. In order to accomplish this, we compared groups of animals that received contusion SCI and intraspinal AAV injections with a control group that received the same contusion injury and no injections.
Animals from all groups demonstrated similar trends of body weight gain and similar pattern of recovery in open-field BBB test, reaching a plateau after 3 weeks post injury. No significant difference was observed at any time point between animals that received contusion injury and intraspinal injections of either AAV-1, -5, -9, -rh10 or -hu11 viral vectors and animals with contusion SCI and no injections (Figures 6a, b) .
Our immunochemistry experiments using a macrophage/ microglia marker ED1 revealed that none of the viral vectors administered intraspinally following contusive SCI generate additional macrophage/microglia response (Figures 6c and d) , known as an index of cellular inflammatory response following SCI in rats. 39, 40 
DISCUSSION
In this study we examined and compared the transduction efficacies and cell tropisms of novel (AAV-rh10 and AAV-hu11) and established (AAV-1, AAV-5 and AAV-9) vectors in damaged spinal cord following intraspinal injections of these vectors after contusion SCI. In addition, we examined the effect of these AAV serotypes on behavioral performance and cellular inflammatory response. None of these vectors were found to induce additional behavioral complications or increased inflammatory responses in SCI animals ( Figure 6 ).
All five serotypes effectively transduced spinal cord tissue, including cells in gray matter and processes in white matter. General GFP expression and transduced area were comparable for all serotypes at the thoracic level in the vicinity of injury/injection site, with the exception of relatively low signal for AAV-hu11. These results demonstrate that all viral vectors studied are excellent vehicles for therapeutic gene delivery to the damaged spinal cord.
At cervical levels, expression was very low, with few GFPpositive cells in gray matter and some GFP-positive processes along the perimeter of white matter in AAV-9 and AAV-rh10. At lumbar levels expression persisted, with GFP signal strongest for AAV-9 and AAV-rh10 and lowest for AAV-hu11. Such targeted robust transduction of discrete spinal tissue (about 3 mm spread rostral/caudal to injection; Figures 1 and 2 ) may be favorable property for gene delivery localized to the penumbra of SCI.
AAV-5, AAV-9 and AAV-rh10 transduced more neurons compared with AAV-1 and AAV-hu11 (Figure 2 ). The intensity of GFP signal in neurons measured in this study was higher in cells transduced with AAV-1, AAV-9 and AAV-rh10 (Figure 3 ). AAV-5 successfully transduced as many neurons as AAV-rh10 and AAV-9; however, there was relatively low GFP signal observed in these cells. This may indicate the possibility of serotype-dependent differences in number of vector genomes delivered to neurons. Additional studies may be necessary to further characterize additional properties of these vectors beyond the number of transduced cells.
All viral vectors tested in this study induced robust transduction of spinal cord tissue and are effective gene delivery systems. An important finding, however, was that AAV-rh10 induced robust transduction of not only neurons but macrophages/microglia and oligodendrocytes as well. Compared with AAV-rh10 all other vectors tested exhibited lower transduction of ED1-and CC1-positive cells in the damaged spinal cord (Figures 4 and 5 ; Table 1 ). This ability of AAV-rh10 to transduce more ED1-positive cells, that is, macrophages/microglia (which are present in high numbers at the injury epicenter and are therefore a good target for therapeutic gene delivery to the damaged spinal cord) is desirable for SCI pathogenesis as it facilitates the delivery of therapeutic genes to the injury epicenter.
The role of glia in SCI is dual. They may contribute to secondary damage or be neuroprotective. 41, 42 The major glial response to SCI includes: (i) secretion of glia-derived scar-related inhibitory factors, such as chondroitin sulfate proteoglycans, 24 including NG2, a major inhibitory factor restricting axonal regeneration 25, 43, 44 and blocking axonal conduction, 28, 29 (ii) changes in the transition of oligodendrocyte precursor cells (known to be NG2-positive) into mature oligodendrocytes, thus affecting axonal myelination and remyelination, 45, 46 (iii) functional changes in astrocytes (that is, reactive astrogliosis), which are the major contributors to glial scar and known to secrete both growth-promoting and -inhibitory factors after SCI, 47, 48 (iv) activation of microglia, the number of which is rapidly elevated in the vicinity of the injury. 49, 50 Another cell type, macrophages, also accumulate close to the injury epicenter and are known to be derived from both microglia and hematogenous macrophages. 40, 51 In many cases these cells are referred to as macrophages/microglia because it is difficult to discriminate between the activated microglia and macrophages in the injured CNS. Macrophages/microglia are among the major cells participating in the inflammatory cell response following SCI. [39] [40] [41] 52 Although the functional role of macrophages/microglia at the injury epicenter is still under debate, the fact remains that macrophages/microglia 'rush' to the contusion injury epicenter following SCI (see Figure 6 ), and thus these cells represent an excellent target for viral-vector-mediated delivery of therapeutic genes to the site of the injury. Thus, revealed in this study for the first time, the ability of AAVrh10 to transduce not only neurons but also glial cells and macrophages/microglia in the damaged spinal cord suggests that AAV-rh10 may be an appropriate vector for delivery of therapeutic genes to the damaged spinal cord following contusion SCI.
Consistent with this view, our recent experiments revealed that AAV-rh10-mediated delivery of Neurotrophin NT3 combined with chondroitinase-ABC (known to degrade the scar-related chondroitin sulfate proteoglycan) 53 by intraspinal injections immediately following T10 contusion SCI in adult rats, improved anatomical plasticity, synaptic transmission through survived fibers and induced the appearance of additional detour synaptic pathways innervating dorsomedial interneurons. 34 These improvements of transmission in animals that received AAV-rh10-NT3/chondroitinase-ABC treatment following contusion SCI associated with improved locomotor function. Our on-going experiments are designed to determine whether intrathecal or intramuscular administration of AAV-rh10 vector, immediately or at delayed time points after SCI, may encourage transduction comparable to that induced by intraspinal injections of this vector.
Further study of transduction efficiencies of different viral vectors and administration at different time points will reveal optimal time points and vectors to introduce different therapeutic gene products for SCI.
MATERIALS AND METHODS

AAV viral vectors
All AAV vectors encoding enhanced GFP gene and expressing CMV promoter (AAV.CMV.PI.EGFP.WPRE.bGH) have been provided by Penn Vector Core at the University of Pennsylvania. AAV-1, -5, -9, -rh10 and -hu11 serotypes used in this study have been constructed by incorporating different viral capsid proteins into the AAV2 recombinant genome. 14 Production, packaging and purification of viral vectors were performed by Penn Vector Core at the University of Pennsylvania. All AAV vectors tested in this study have been adjusted to have equivalent dosages of genome copies (6.8 × 10 12 GC ml 
SCI and vector delivery
All procedures were approved by the Institutional Animal Care and Use Committee at SUNY-Stony Brook and Northport VAMC. Adult, female Sprague-Dawley rats (~220 g; Taconic Farms, Germantown, NY, USA) were deeply anesthetized with 3% isoflurane in 100% O 2 followed by 1.5% isoflurane in 100% O 2 to maintain an anesthetic state during surgery. Rats were given an injection of Buprenorphine (0.01 mg kg
) before surgery to reduce post-operative pain and placed on a water-circulating heat pad. Body temperature was monitored by a rectal thermometer and maintained at 36-37°C. Dorsal laminectomy was performed to expose the dorsal surface of the T10 spinal cord. Contusion injuries (150 kDyn force) were performed using an IH-0400 Impactor device (2.5 mm probe diameter; Precision System and Instrumentation, Lexington, KY, USA) as previously described. 34 Immediately following the injury, animals received one of five AAV serotypes (AAV-1, -5, -9, -rh10 or -hu11) as intraspinal injections. Specifically, four intraspinal injections of 0.5 μl each were made into the left and right spinal cord, 1 mm lateral of midline at 1.5 mm depth, 1.2 mm rostral and 1.2 mm caudal to the injury epicenter (that is, edge of the bruise). Following the injury and vector injections, muscles and skin were closed and subcutaneous injections of antibiotic (Baytril 5 mg kg − 1 ) and 5 ml of sterile lactated Ringer's solution were administered. The rats were housed individually and received injections of Baytril, Buprenorphine and lactated Ringer's for 3 days following surgery.
Tissue processing and immunohistochemistry
Ten weeks post injury and AAV administration, rats received an overdose bolus of urethane and were transcardially perfused with 400 ml of 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Spinal cords were removed and post-fixed 1-2 h in 4% paraformaldehyde followed by cryoprotection for a minimum of 48 h in a 30% sucrose solution. Following cryoprotection, spinal cord segments were cut rostrocaudally on a cryostat at a thickness of 40 μm, and sections were collected serially on Colorfrost Plus slides (ThermoFisher Scientific, Waltham, MA, USA) in seven sets. Segments T9-T11, containing the injury site, were sectioned horizontally. The remainder of cervical, thoracic and lumber segments (C1-T8 and T12-L6) was sectioned in the transverse plane.
All spinal cords and sections were processed using the same time table and protocols. All sections were stored at 4°C, protected from light and imaged within 48 h of sectioning.
One complete set was stained with Cresyl Violet and used to confirm the spinal cord segment level as well as for injury reconstruction. The remaining sets were used for quantitative analysis and immunofluorescence staining to identify transduced cell types. Various cell-specific antibodies were used for immunofluorescence studies: mouse anti-CD68 (ED1; 1:200; Abcam, Cambridge, MA, USA) to detect macrophages/ microglia, mouse anti-APC (CC1; 1:100; Abcam) to detect oligodendrocytes, mouse anti-NeuN (1:600; Millipore, Billerica, MA, USA) to detect neurons, rabbit anti-GFAP (1:500; Dako, Carpinteria, CA, USA) to detect astrocytes and rabbit anti-NG2 (1:500; antibody generously supplied by Dr Joel Levine) to detect NG2. Briefly, sections were blocked in 0.1 m PBS containing 6% normal goat serum and 0.3% Triton X-100 and then incubated overnight at 4°C in one of the above antibodies. After rinsing several times with 0.1 m PBS, sections were incubated at room temperature in either goat-anti-mouse or goat-anti-rabbit secondary antibody (Alexa Fluor 594, Invitrogen; 1:800 dilution) for 1 h. Sections were then rinsed in PBS, dipped briefly in dH 2 
Quantitative analysis
Total number of transduced neurons. Quantitative analysis was performed by researchers who were blinded to the AAV serotypes of the cases under review. The number of transduced neurons at different spinal levels was calculated as an average of the manually counted cells exhibiting colocalization of GFP and NeuN signal in five cross-sections separated by 80 μm at each spinal level (C1-T8 and T12-L6). One set of Cresyl Violetstained sections was used to determine the spinal segment level. The number of NeuN-labeled cells in the sections from the given segments was consistent and not significantly different (P40.05) among all animals studied. For example, the number of NeuN-labeled cells per section was 680-730 cells in cervical C4,~450-490 cells at thoracic T8,~510-560 cells at thoracic T12 and~920-990 cells in lumbar L3 levels.
GFP intensity. All images that were used to measure GFP intensity were captured with a Zeiss AxioCam MRm camera using identical settings. A maximum of 10 randomly selected transduced cells with neuronal morphology in gray matter in all sections of one complete series were manually outlined and the mean GFP intensity was measured using the Zeiss Axiovision v4.8 software.
Transduction area. Transduced area per section for one complete set was measured using the ImageJ software (National Institute of Health, Bethesda, MD, USA). Thresholded pixel area was calculated by eliminating background and quantifying only GFP-positive signal area. The resulting value was divided by the total area of the section to give the percentage of GFP-positive area per section.
ED1 immunoreactivity. To quantify ED1 immunoreactivity, one complete set of horizontal sections from the T9 to T11 segment, containing the injury epicenter, for each rat was immunostained with ED1. Images were captured using identical settings and ED1-positive signal was calculated after thresholding and eliminating background intensity using the ImageJ software. 34 Because of difficulties distinguishing densely packed individual ED1-positive cells at the injury epicenter, the area of colocalization was measured in order to compare the number of transduced macrophages/ microglia between serotypes. Area of GFP-positive cells that were also immunolabeled with ED1 was measured, using the ImageJ software color thresholding tool, and percent out of total area of ED1-positive immunoreactive cells was calculated for a fixed (1 × 0.7 mm 2 ) area for each section at the injury epicenter.
CC1 immunoreactivity.
To compare the number of transduced oligodendrocytes, one complete set from the T9 to T11 segment was immunostained with anti-APC (CC1) antibody, and the percent of cells that were positive for both GFP and CC1 signals out of the total number of cells immunostained with CC1 was calculated within four fixed (0.5 × 0.3 mm 2 each) areas bilaterally within intact white matter just rostral and caudal to injury, for each section.
Behavioral performance and body weight
In order to examine the effects of intraspinal injections of AAV vectors on behavioral performance and body weight, animals from AAV serotype groups were compared with a group of animals that received the contusion SCI but no AAV injections. Open-field BBB 54 score was used to assess behavioral performance. Body weights of all rats were monitored and compared between groups. Baselines for BBB and body weight were determined before injury, and then recorded 3 days post injury and weekly.
Statistical analysis
Data were analyzed using the SigmaPlot 11.0 software (Systat Software Inc, San Jose, CA, USA). A one-way ANOVA or one-way ANOVA on ranks followed by Tukey's or Dunn's multiple comparisons post hoc tests were used to compare the data. Results were considered statistically significant for Po0.05. Data are means ± s.e.
